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Objective: The US Food and Drug Administration–approved trial, “A Phase 1, Open-Label, First-in-Human, Feasibility
and Safety Study of Human Spinal Cord-Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic
Lateral Sclerosis, Protocol Number: NS2008-1,” is complete. Our overall objective was to assess the safety and feasi-
bility of stem cell transplantation into lumbar and=or cervical spinal cord regions in amyotrophic lateral sclerosis
(ALS) subjects.
Methods: Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the
safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5
unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral
lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal-mounted stabilization and
injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject
assessments included detailed pre- and postsurgical neurological outcome measures.
Results: The cervical injection procedure was well tolerated and disease progression did not accelerate in any sub-
ject, verifying the safety and feasibility of cervical and dual-targeting approaches. Analyses on outcome data revealed
preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures
that closely correlate with ALS Functional Rating Scale-Revised scores, a standard assessment for ALS clinical trials.
Interpretation: This is the first report of cervical and dual-targeted intraspinal transplantation of neural stem cells in
ALS subjects. This approach is feasible and well-tolerated, supporting future trial phases examining therapeutic dos-
ing and efficacy.
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There is growing interest in the use of stem cells
1–10 as
a therapy in amyotrophic lateral sclerosis (ALS), a
lethal neurological disorder characterized by the degener-
ation of motor neurons. Stem cells offer a means to
replace lost cells, provide neurotrophic support, and
improve the diseased microenvironment.1,7–10 Preclinical
in vitro and in vivo evidence supports the therapeutic
translation of stem cells,9 and studies by our group and
others demonstrate that human spinal stem cells (HSSCs)
produce protective growth factor profiles, differentiate
into neurons, form synapses with host motor neurons,
and have beneficial effects after intraspinal transplanta-
tion in G93A-SOD1 rats, an established model of
ALS.2–6
In 2009, the US Food and Drug Administration
(FDA) approved a phase 1 clinical trial examining the
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safety and feasibility of HSSC injections into the spinal
cords of 18 ALS subjects. HSSCs were delivered using a
novel intraspinal stabilization and injection device devel-
oped by our group.11–14 The first 12 trial subjects, repre-
senting Cohorts A to C, received HSSC transplants into
the L2–L4 lumbar segments of the spinal cord. Group A
subjects were nonambulatory and received 5 unilateral
(A1, n 5 3) or 10 total bilateral (A2, n 5 3) lumbar
injections. Subjects in Groups B and C were ambulatory
and received 5 unilateral (n 5 3) or 10 total bilateral (n
5 3) lumbar injections, respectively. As previously
described, interim results from these first 12 subjects
demonstrated no serious adverse events associated with
HSSC transplantation.15,16
Those encouraging results along with the critical
need to maintain respiratory function in ALS subjects
enabled FDA approval to complete HSSC injections into
C3–C5 cervical segments of the spinal cord, the region
where motor neurons involved in diaphragmatic function
reside. To support these injections, the lumbar stabiliza-
tion and injection device was adapted and optimized for
cervical intraspinal HSSC delivery.12–14 Ambulatory sub-
jects in Groups D (n 5 3) and E (n 5 3) received 5
unilateral cervical injections. Based on previous preclini-
cal data demonstrating enhanced therapeutic efficacy of
HSSC transplantation when injections were targeted to
multiple spinal cord segments,2,4 subjects in Group E
were the same subjects who previously received bilateral
lumbar injections as part of Group C. This cohort repre-
sents the first examination of the feasibility of targeting
both lumbar and cervical spinal cord segments in ALS
subjects in separate surgeries.
The phase 1 trial consisting of 18 intraspinal trans-
plantation surgeries in 15 ALS subjects was completed in
May 2013. Here, we present the functional outcome
data from the 6 subjects undergoing cervical stem cell
transplantation surgery, including 3 subjects receiving
both bilateral lumbar and unilateral cervical HSSC trans-
plants. Data are also presented from the continued
follow-up of the first 12 subjects receiving lumbar intra-
spinal HSSC transplants. Overall, results demonstrate
that HSSCs can be safely transplanted into both lumbar
and=or cervical human spinal cord segments, warranting
future trial phases focused on cellular dosing and thera-
peutic efficacy.
Patients and Methods
Trial Design and Subject Selection
The goals of this phase 1 trial were to assess the safety and tol-
erability of the surgical procedure and the presence of neural
stem cells in the spinal cord, and to examine the use of immu-
nosuppression in ALS subjects, using a risk escalation study
design consisting of 5 subject cohorts.7,15,16 Subject selection
criteria, demographics, and inclusion and enrollment criteria for
Groups A to C have been previously described.15,16 For Groups
D and E, inclusion criteria were the same as for Group B with
the additional requirement of demonstrable arm weakness with
an ALS Functional Rating Scale-Revised (ALSFRS-R) arm sub-
score between 1 and 3; all Group E subjects were recruited
from Group C and had received prior lumbar intraspinal stem
cell injections.17 Detailed inclusion and exclusion criteria are
available at http:==www.clinicaltrials.gov=ct2=show=NCT0134
8451.
Neural Stem Cell Selection
The NSI-566RSC HSSC line used in the trial has been previ-
ously described.6,18,19 The cells are stored under Current Good
Manufacturing Practice (CGMP) conditions and delivered to
the surgery site at a concentration of 10,000 cells=ll.15,16 Cell
viability was assessed prior to each surgery to ensure the
required viability of at least 70% to proceed with
transplantation.15,16
Cervical Stem Cell Transplantation Approach
For Cohorts D and E, adaptations were made to the lumbar
stabilization and injection device and surgical procedure11–16 to
accommodate cervical injections, including redesign of the
mounting platform to adhere the device caudally to the C7 ver-
tebrae and rostrally at the base of the skull.12–14 Briefly, stand-
ard anesthetic and monitoring techniques were adhered to
similar to those for lumbar injections,15,16 and the surgical pro-
cedure for Groups D and E involved a C3–C5 laminectomy.
Subjects received 5 unilateral injections spaced 4mm apart. Ten
microliters was delivered at a rate of 5ll=min over 2 minutes,
for a total of 500,000 cells in the 5 injections. Following com-
pletion of all injections, the dura and tissue incisions were
closed and postoperative subject care was managed as previously
described.15,16 A conservative lifelong, multiagent immunosup-
pression approach was employed for the phase 1 trial.15,16 For
additional details of the cervical microinjection device, surgical
procedure, and immunosuppression regimen for subjects in
Groups D and E, refer to our technical approach and safety
outcome report.17
Subject Assessments
All subjects received magnetic resonance imaging (MRI) during
screening to calculate precise injection positioning and to serve
as a baseline for the assessment of postoperative MRI scans,
which will be analyzed and reported separately. To determine
progression of disease status, subjects regularly underwent
standard clinical evaluations as well as regular functional assess-
ments, including ALSFRS-R, seated forced vital capacity
(FVC), grip strength assessment (GST), hand-held dynamome-
try (HHD), electrical impedance myography (EIM), and blad-
der ultrasounds.15–17 Group A subjects were not ambulatory;
these subjects were evaluated once preoperatively and regularly
following transplantation. All remaining subjects in Groups B,
C, and D were evaluated monthly for 3 months before surgery
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to establish a standard slope of disease progression and regularly
following transplantation. Group E subjects previously received
lumbar stem cell transplants as Group C; therefore, functional
assessment schedules were already underway prior to surgery
and were continued regularly following cervical transplantation.
The schedule of all pre- and postoperative assessments is sum-
marized in Supplementary Table 1.
Although this was a phase 1 trial and functional outcome
data were collected for the purpose of assessing safety, secondary
analyses of these data were performed as a means to gain
insight into how cellular transplantation affected disease pro-
gression rates and to inform outcome assessment approaches in
future trial phases. Presurgical disease progression rates for the
various functional outcome measures were first calculated using
linear regression analyses for subjects with multiple available
presurgical outcome assessment data points. These slopes were
utilized to determine whether postsurgical assessment data
points at 6, 9, 12, and 15 months were improved relative to
predicted points extrapolated from the presurgical progression
rates. In addition, Pearson correlation analyses were performed
using available data points for the various functional measures
to determine which outcome assessments most closely correlated
with ALSFRS-R scores. Finally, we calculated progression rate
slopes for ALSFRS-R scores and GST outcomes based on data
points across 9-month sliding windows to determine whether
there were periods where progression rates were attenuated or
improved relative to the presurgical progression rate. These
analyses were performed for Group E subjects (individuals who
received both lumbar and cervical transplantation), as they had
the largest amount of available assessment data. Plotted values
represent slopes generated from the available data points within
each 9-month window. Best-fit curves were then generated for
each subject using fourth-order polynomial analyses. All statisti-
cal analyses and curve fitting utilized R version 3.0.1
(http:==cran.r-project.org=) and Prism 6 for Windows (Graph-
Pad, SanDiego, CA).
Results
Subject Selection and General Surgical
Outcomes
Subject demographics for all cohorts are presented in
Table 1. Enrolled subjects included 13 males and 2
females ranging in age from 35 to 66 years old. Disease
TABLE 1. Subject Demographics
Group Surgery
Details
Subject
Number
Surgery
Number
Subject
Age at
Surgery,
yr
Disease
Duration
at Surgery,
yr
Gender Death, mo
Postsurgery
A1 Nonambulatory 1 1 61.8 5.2 M 30
unilateral 2 2 43.4 12.7 M
lumbar 3 3 51.1 2.1 M 13
A2 Nonambulatory 4 4 37.5 2 M
bilateral 5 5 66.3 2.2 M 19
lumbar 6 6 55 2.2 M 9
B Ambulatory 7 7 59 1.6 M
unilateral 8 8 41.1 5.6 M
lumbar 9 9 54.6 1.3 M 11
C/E Ambulatory 10 10 48.9 11.6 M
bilateral 16 50.2 13
lumbar 11 11 39.3 1.6 M
and 18 40.7 3
unilateral 12 12 65.1 3 M
cervical 17 66.3 4.3
D Ambulatory 13 13 50.3 3.1a M 20
unilateral 14 14 54.3 1.8a F 7
cervical 15 15 35.2 1.7 F
F 5 female; M 5 male.
aSubject demonstrated features of bulbar onset amyotrophic lateral sclerosis.
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duration ranged between 1.3 and 13 years at the time of
surgery. All Group E subjects, 1 of 2 trial cohorts desig-
nated to receive cervical stem cell transplants, previously
received lumbar stem cell transplants as Group C. In
total, 15 ALS subjects underwent 18 surgeries.15–17
Overall, the procedure was well tolerated across all
cohorts, with minimal perioperative or postoperative
complications. Only a nominal number of serious
adverse events were observed during the course of the
phase 1 trial.17 For cervical injections in Groups D and
E, detailed reports on the intraoperative and the immedi-
ate postoperative surgical outcomes and morbidity data
are presented in our recent technical approach and safety
outcome report.17
At this point, 7 subject deaths have occurred (see
Table 1). As previously reported, Subject 6 died suddenly
and unexpectedly 8 months postsurgery due to a congen-
ital cardiac defect, and Subject 3 died of respiratory fail-
ure associated with disease progression 13 months
postsurgery.15,16 Subjects 1, 5, 9, 13, and 14 also died of
respiratory complications associated with ALS disease
progression at 30, 19, 11, 20, and 7 months postsurgery,
respectively. All patients underwent autopsy for analysis
of tissue response to implantation and for the identifica-
tion of the continued presence of the transplanted cells
within the spinal cord. The detailed results of these anal-
yses will be reported separately. Briefly, standard patho-
logical analysis showed no evidence of hemorrhage, cyst
formation, or inflammatory reaction within the sites of
transplantation. A representative example of the initial
postmortem morphological findings is presented for Sub-
ject 14 (Fig 1). This subject received cervical injections
and died 7 months postsurgery. There were no morpho-
logical abnormalities within the sites of transplantation;
however, a nest of cells likely composed of the trans-
planted cells was identified.
Functional Outcome Measures
Subjects regularly (see Supplementary Table 1) under-
went clinical assessments. Interim results from Subjects 1
to 12 demonstrated no obvious acceleration of disease
progression, and Subject 11 in Group C demonstrated
modest improvements in postoperative ALSFRS-R,
HHD, and EIM measurements.15 Continued functional
outcome measure monitoring for Group A and B sub-
jects is presented and discussed in Supplementary Figures
1 and 2, respectively. Overall, these subjects continued to
demonstrate outcomes consistent with disease progres-
sion, but no acceleration of the disease course.
GROUP D: CERVICAL INJECTION. Functional out-
comes are presented in Figure 2. Subjects 13 and 14
both had features of bulbar ALS. Subject 13 developed
cervical kyphosis17 and died 20 months following trans-
plantation, and Subject 14 died 200 days following trans-
plantation. Although other clinical markers remained
FIGURE 1: Neuropathological findings in Subject 14. (A) Gross image of cervical spinal cord at the time of autopsy. Serial sec-
tions through the region of transplantation did not demonstrate regions of cystic change, hemorrhage, or significant tissue dis-
ruption. (B) Representative cross section showing intact cord morphology using hematoxylin and eosin (H&E) staining. There is
a nest of cells (circled) that are not intrinsic to the spinal cord, and do not stain with glial or neuronal markers (not shown). (C)
Higher power of circled region in B showing the morphology of these cells, which is reminiscent of the morphology of the
stem cells prior to transplantation (inset, H&E).
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stable, Subject 15 demonstrated a modest decline in
ALSFRS-R and HHD following transplantation, reflect-
ing a progression that appeared slower than what is typi-
cally expected for ALS.
GROUP E: DUAL-TARGETED INJECTIONS. Func-
tional outcome measures are presented in Figure 3. Sub-
ject 10 had a long disease duration and maintained a
steady ALSFRS-R score accompanied by mild declines in
other functional measures, suggestive of a very slowly
progressive form of ALS. Subjects 11 and 12 had
improved ALSFRS-R scores, steady FVC values, and
modest declines in HHD megascores following HSSC
transplantation, suggesting some progression of disease
accompanied by multiple improved functional measures.
ADVANCED ANALYSES OF FUNCTIONAL OUTCOME
MEASURES. We performed additional analyses to gain
insight into the effects of the intervention on disease pro-
gression and to identify appropriate functional outcome
FIGURE 2: Evaluation of disease progression in Group D subjects. Disease progression for Subjects 13 to 15 as measured by
(A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), (B) forced vital capacity (FVC), (C, D) hand-held
dynamometry (HHD), (E, F) grip strength assessment (GST), and (G, H) electrical impedance myography (EIM). HHD is shown as
a composite megascore for upper (C) or lower (D) extremities, normalized to the percentage of the score at baseline. GST
data are presented for left (E) and right (F) sides. EIM is shown as 50kHz phase all muscle average for upper (G) or lower (H)
extremity muscles. X-axis represents days pre- or postsurgery (day of surgery 5 day 0). Note that there were no precipitous
declines in function after surgery for any subject. Note that a score of 0 for Subject 14 indicates subject death on the day
post-transplantation indicated on the x-axis.
Feldman et al.: ALS Stem Cell Transplantation
March 2014 367
measures for future trial phases. Comparison of postsurgi-
cal outcome data to predicted outcome points extrapolated
from presurgical disease progression slopes revealed
improvements in a significant number of measures at 6, 9,
12, and 15 months postsurgery (Table 2). Of the 8 out-
come assessments, at least 5 measures were improved in
>50% of subjects at each time point relative to the pre-
dicted outcome values extrapolated from presurgical pro-
gression rates. To identify which functional assessments
coordinated most closely with ALSFRS-R scores, Pearson
correlations were calculated between data points for the
various functional outcome measures. Results indicate
that GST measures most closely reflect ALSFRS-R values
throughout the study period (Fig 4), suggesting that
ALSFRS-R and GST assessments will provide important
outcome information in future trial phases.
As shown in Figure 5, analysis of ALSFRS-R scores
for Group E subjects exhibits improved outcomes (slope
FIGURE 3: Evaluation of disease progression in Group E subjects. Disease progression for Subjects 10 to 12 as measured by
(A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), (B) forced vital capacity (FVC), (C, D) hand-held
dynamometry (HHD), (E, F) grip strength assessment (GST), and (G, H) electrical impedance myography (EIM). HHD is shown as
a composite megascore for lower (C) or upper (D) extremities, normalized to the percentage of the score at baseline. GST
data are presented for left (E) and right (F) sides. EIM is shown as 50kHz phase all muscle average for upper (G) or lower (H)
extremity muscles. X-axis represents days before or after lumbar surgery (day of surgery 5 day 0). Note that there were no
precipitous declines in function after surgery for any subject. Note that Group E subjects are subjects initially enrolled in Group
C who received lumbar stem cell injections, and the short dotted vertical bars indicate the number of days after the first sur-
gery when the second stem cell transplantations (cervical injections) were administered. Note that Subject 11 (purple lines)
showed apparent improvement in ALSFRS-R and upper and lower extremity HHD.
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values higher than the presurgical slope at baseline reflect
improved or attenuated progression rates during the des-
ignated window) beginning within the first month post-
surgery, with slopes remaining positive for windows
beginning up to 6 months postsurgery. Although the rate
of benefit then decreases over time, the overall progres-
sion rate generally remains attenuated relative to the pre-
surgical slope through the time of the second surgery.
Positive slopes are again observed across treatment win-
dows beginning at approximately 13 to 14 months post-
surgery for these subjects, reflecting the second HSSC
transplant in Subjects 10, 11, and 12 at 490, 532, and
464 days, respectively. This bimodal representation of
HSSC benefit suggests that the biological activity of the
cells shows the greatest benefits in the 6 months immedi-
ately following the surgeries (see Fig 5B), continuing to
provide some benefit throughout the study evaluation
period. Similar analyses of GST data for this cohort
reflect comparable trends (data not shown).
Discussion
In this completed FDA-approved phase 1 trial, 18 intraspi-
nal transplantation surgeries in 15 ALS subjects were per-
formed following a risk escalation paradigm, progressing
from nonambulatory to ambulatory subjects, lumbar to
cervical spinal cord segments, and unilateral to bilateral
injections across 5 cohorts. The encouraging interim
results from Groups A to C,15,16 representing 12 subjects
who received lumbar injections, supported the completion
of the final trial with Cohorts D and E, examining cervical
injections in 6 ALS subjects. Notably, the final 3 subjects
receiving cervical injections previously received bilateral
lumbar injections. Our study represents the first report of
successful intraspinal stem cell transplantation into the cer-
vical spinal cord and of successful repeated intraspinal stem
cell transplantation into lumbar and cervical spinal cord
segments in ALS subjects in an FDA-approved trial. Our
ability to directly inject stem cells to target motor neurons
in the region of the cervical spinal cord responsible for res-
piration represents a significant advance in the field of cel-
lular therapy. In parallel, the dual-targeting approach, that
is, both cervical and lumbar transplantation, has the poten-
tial to preserve respiratory function and improve motor
function in ALS subjects.4 What is now required are future
studies to determine whether these approaches provide sus-
tained clinical improvement in ALS.
Of the 15 subjects in the phase 1 trial, 6 subjects
died of their disease and 1 subject died of a congenital
heart defect unrelated to ALS between 7 and 30 months
after surgery. Of the 8 subjects who are still alive, 3 of
them (Subjects 2, 8, and 10) had a long disease course
prior to surgery (5.6, 11.6, and 12.7 years of known dis-
ease), likely representing atypical ALS, and have had little
change in the trajectory of their disease. Subjects 7, 11,
FIGURE 4: Pearson correlations for outcome assessment measures. ALSFRS 5 Amyotrophic Lateral Sclerosis Functional Rating
Scale; EIM 5 electrical impedance myography; FVC 5 forced vital capacity; GST 5 grip strength assessment; HHD 5 hand-held
dynamometry.
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12, and 15, who are alive with very slowly progressive or
stabilized disease, had 2 clinical characteristics in com-
mon: these individuals had no bulbar features of ALS,
and surgical transplantation occurred early within the
course of their disease (average of 2 years and 1 month
after symptom onset at the time of surgery). These pre-
liminary results raise the possibility that intraspinal stem
cell transplantation of ALS subjects with no bulbar symp-
toms early in the course of their disease could slow dis-
ease progression or even allow for functional
improvement.
The majority of ALS trials utilize subject survival
and ALSFRS-R scores for primary outcome measures.20
Our data demonstrate that GST most closely correlates
with the ALSFRS-R scores. Comparisons of presurgical
slopes to post-transplant data revealed that >50% of sub-
jects demonstrated improvement across multiple clinical
measures at 6, 9, 12, and 15 months postsurgery. Look-
ing specifically at ALSFRS-R scores at the 9-month time
point, the subjects who demonstrated improvements were
part of Groups B, C, and E and exhibited an average dis-
ease duration <2 years prior to surgery, again suggesting
that only subjects early in the disease course may experi-
ence clinical benefit. However, our experience did dem-
onstrate a wide variation in presurgical progression rates
for those individuals with multiple data points, empha-
sizing the importance of sufficient lead-in data to deter-
mine efficacy. Average declines of 21.1 ALSFRS-R score
per month (213.32 per year) have been reported20; how-
ever, the varied slopes we observed and the heterogeneous
FIGURE 5: Preliminary analysis of potential windows of human spinal stem cell (HSSC) biological activity in Subjects 10 to 12.
To identify the most biologically active period of the injected HSSCs, postsurgery data points for Group E subjects were
divided into a series of 9-month windows, beginning each month postsurgery, and slopes were calculated across each window.
Slopes were also calculated using Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) data points for the
presurgical window. (A) The top panel demonstrates ALSFRS-R scores for Group E subjects during the presurgical period
(green) and representative ranges associated with the various sliding postsurgical 9-month windows (dark blue). The bottom
panel demonstrates the slopes obtained for each sliding window, with the x-axis corresponding to the first month for each 9-
month window (ie, window 1 corresponds to months 1–10 postsurgery, window 2 corresponds to months 2–11 postsurgery,
window 3 corresponds to months 3–12 postsurgery, etc). The first plotted slope for each subject corresponds to their presurgi-
cal progression rate. Slope values higher than the presurgical slope at baseline represent improved or attenuated progression
rates during the designated window. Note that the starting month of the final sliding window for each patient coincides with
the dates of the second surgery, which occur at 17.5, 19, and 16.6 months after the initial Cohort C surgery (time 0) for Sub-
jects 10, 11, and 12, respectively. (B) The presurgical slope and postsurgical slopes associated with the window correlating to
the peak benefit windows for both the lumbar and cervical postsurgery time frames are summarized.
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presentation of ALS emphasize the need for subject-
specific baseline data.
We acknowledge that this study was not powered
to determine efficacy and there was no control arm. In
addition, some subjects exhibited a significant disease
burden prior to surgery and were unlikely to show bene-
fit, sufficient preclinical data points were unavailable for
some subjects, and best-fit presurgical slopes were not
always significantly powered given the number of avail-
able data points. Despite these limitations, we were able
to identify potential possible therapeutic windows in our
advanced evaluation of Group C=E outcome data. Of
note, the 3 subjects in this cohort received the highest
number of injections and demonstrated the largest effects
on progression rates, suggesting that more injections are
better, consistent with the neuroprotective mechanism of
action hypothesized for this cell therapy.7,9 The ability to
successfully administer 1.5 million HSSCs to ALS sub-
jects over 15 total injections in Group E subjects into
both lumbar and cervical spinal cord segments over the
course of 2 surgeries is an important first step in evaluat-
ing the tolerance of the spinal cord for multiple HSSC
transplantation procedures. The observed bimodal distri-
bution in the 9-month sliding window slope analysis sug-
gests there are maximal periods of benefit that correlate
with the 2 surgical interventions. Furthermore, as the
bell-shaped benefit curve associated with each interven-
tion is likely due to disease progression, increasing the
total cell dose and applying multiple applications of the
stem cells may increase both the length and magnitude
of potential benefit. These very preliminary observations
on only 3 subjects provide the framework for future dis-
cussions of trial designs.
In conclusion, as we move forward, the continued
assessment of data collected from subjects participating
in phase 1 of the trial, evaluation of postsurgical MRI
data, and characterization of the cellular grafts in
deceased subjects will provide further insight into the
therapeutic mechanisms and potential efficacy of intraspi-
nal stem cell transplantation in ALS. With improved def-
initions for subject selection criteria, careful evaluation of
clinical history prior to surgery, and utilization of the
most efficient neurological assessment measures, we are
primed for continued progress in future trial phases.
Phase 2 of this trial commenced in September 2013
(ClinicalTrials.gov identifier: NCT01730716).
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